Stocks Of Covid-related Medicines Remain Unused

Gujarat News, Gujarati News, Latest Gujarati News, Gujarat Breaking News, Gujarat Samachar.

Latest Gujarati News, Breaking News in Gujarati, Gujarat Samachar, ગુજરાતી સમાચાર, Gujarati News Live, Gujarati News Channel, Gujarati News Today, National Gujarati News, International Gujarati News, Sports Gujarati News, Exclusive Gujarati News, Coronavirus Gujarati News, Entertainment Gujarati News, Business Gujarati News, Technology Gujarati News, Automobile Gujarati News, Elections 2022 Gujarati News, Viral Social News in Gujarati, Indian Politics News in Gujarati, Gujarati News Headlines, World News In Gujarati, Cricket News In Gujarati

Stocks Of Covid-related Medicines Remain Unused

| Updated: June 6, 2022 14:22

It is amazing how with time the tides change. There was a time in 2020, when India was struggling to meet the demand for remdesivir in the domestic markets. While patients were anxiously waiting to receive a single dose, pharmacies were scrambling to cater to them as the manufacturers toiled to meet orders. During this period, all manufacturers significantly increased their production of remdesivir.

However, its mid-2022 now and things have taken a completely different turn. On the positive side, Covid-19 is under control. However, this means that several pharmaceutical manufacturers will have to take a financial hit as they have stocks of remdesivir that might never be used. There is no demand for the drug in the country and many chemists have already returned their stocks to the company. There is also no demand in the international market.

Estimates show that currently there is a stock of 60 lakh remdesivir vials that might never get used. As such, these vials, worth Rs600 crore, may need to be destroyed as they will expire early next year.

According to sources, through out India, Covid-related medicines worth Rs 800-1,000 crore remain unused. This also includes remdesivir active pharmaceutical ingredients (APIs) valued at Rs200 crore.

Your email address will not be published. Required fields are marked *